Armata Pharmaceuticals published a study detailing the structure of phage P7-1, part of their AP-PA02 cocktail targeting Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis patients. Using advanced cryo-electron microscopy, the research uncovered how P7-1's unique tail fibers contribute to its stability and infection mechanism. This insight supports Armata's development of phage therapies as alternatives to antibiotics, with AP-PA02 showing promise in Phase 2 trials. The findings pave the way for engineering more effective and stable phage treatments against resistant bacterial infections.
Deere & Company announced a quarterly dividend of $1.62 per share, payable on August 10, 2026. The dividend will be paid to shareholders of record as of June 30, 2026. This dividend declaration reflects the company's ongoing commitment to returning v...
Tesla shares gained as investors reacted to a 67.2% year-over-year increase in European electric vehicle sales and speculation about a potential future merger with SpaceX. Tesla sold 9,169 vehicles in Europe in April, with year-to-date sales up 61.7%...
Modine Manufacturing is pivoting from traditional markets to focus on advanced AI cooling solutions for hyperscale data centers. The company has beaten earnings and revenue estimates for four consecutive quarters, reporting $1.71 earnings per share a...
The global fleet telematics market is projected to grow from $10.42 billion in 2025 to $21.95 billion by 2032, at an 11.2% CAGR. Growth is fueled by increased adoption of advanced telematics in commercial vehicles for operational efficiency, predicti...
Bank of Nova Scotia reported strong Q2 fiscal 2026 results, with adjusted earnings of $1.47 per share beating the $1.46 estimate and revenue of $7.17 billion surpassing expectations. Key segments showed growth: Canadian Banking earnings rose 53%, Int...
